{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:54:11Z","timestamp":1790096051573,"version":"4.0.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,12]]},"DOI":"10.7759\/cureus.87776","type":"journal-article","created":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T13:56:46Z","timestamp":1752328606000},"source":"Crossref","is-referenced-by-count":2,"title":["Rupture of Abdominal Aortic Aneurysm After Bevacizumab Treatment for Colorectal Cancer"],"prefix":"10.7759","author":[{"given":"Naoki","family":"Uemura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Saitoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Shiotsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigehiko","family":"Uchino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinshu","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1159\/000488087","article-title":"Anti-angiogenics: current situation and future perspectives","volume":"41","author":"Zirlik K","year":"2018","unstructured":"Zirlik K, Duyster J. Anti-angiogenics: current situation and future perspectives. Oncol Res Treat. 2018, 41:166-71. 10.1159\/000488087","journal-title":"Oncol Res Treat"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: A review of 15\u00a0years of clinical experience and future outlook","volume":"86","author":"Garcia J","year":"2020","unstructured":"Garcia J, Hurwitz HI, Sandler AB, et al.. Bevacizumab (Avastin\u00ae) in cancer treatment: A review of 15\u00a0years of clinical experience and future outlook. Cancer Treat Rev. 2020, 86:102017. 10.1016\/j.ctrv.2020.102017","journal-title":"Cancer Treat Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0029","article-title":"Colon cancer, version 3.2024, NCCN Clinical Practice Guidelines in oncology","volume":"22","author":"Benson AB","year":"2024","unstructured":"Benson AB, Venook AP, Adam M, et al.. Colon cancer, version 3.2024, NCCN Clinical Practice Guidelines in oncology. J Natl Compr Canc Netw. 2024, 22:10.6004\/jnccn.2024.0029","journal-title":"J Natl Compr Canc Netw"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603813","article-title":"Mechanisms of adverse effects of anti-VEGF therapy for cancer","volume":"96","author":"Kamba T","year":"2007","unstructured":"Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007, 96:1788-95. 10.1038\/sj.bjc.6603813","journal-title":"Br J Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.hjc.2016.11.022","article-title":"Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer","volume":"58","author":"Kapelakis I","year":"2017","unstructured":"Kapelakis I, Toutouzas K, Drakopoulou M, et al.. Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer. Hellenic J Cardiol. 2017, 58:215-9. 10.1016\/j.hjc.2016.11.022","journal-title":"Hellenic J Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.081","article-title":"Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis","volume":"23","author":"Hicklin DJ","year":"2005","unstructured":"Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005, 23:1011-27. 10.1200\/JCO.2005.06.081","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-22-0794","article-title":"JCS\/JSCVS\/JATS\/JSVS 2020 guideline on diagnosis and treatment of aortic aneurysm and aortic dissection","volume":"87","author":"Ogino H","year":"2023","unstructured":"Ogino H, Iida O, Akutsu K, et al.. JCS\/JSCVS\/JATS\/JSVS 2020 guideline on diagnosis and treatment of aortic aneurysm and aortic dissection. Circ J. 2023, 87:1410-621. 10.1253\/circj.CJ-22-0794","journal-title":"Circ J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-008-0583-0","article-title":"Multiple primary cancers in extracolonic sites with colorectal cancer","volume":"24","author":"Lee SH","year":"2009","unstructured":"Lee SH, Ahn BK, Baek SU. Multiple primary cancers in extracolonic sites with colorectal cancer. Int J Colorectal Dis. 2009, 24:301-4. 10.1007\/s00384-008-0583-0","journal-title":"Int J Colorectal Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray F","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al.. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024, 74:229-63. 10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2005.05.132","article-title":"Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy","volume":"333","author":"Ferrara N","year":"2005","unstructured":"Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005, 333:328-35. 10.1016\/j.bbrc.2005.05.132","journal-title":"Biochem Biophys Res Commun"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz H","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, et al.. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004, 350:2335-42. 10.1056\/NEJMoa032691","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-024-03134-w","article-title":"Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a systematic review and meta-analysis","volume":"24","author":"Song Y","year":"2024","unstructured":"Song Y, Mao Q, Zhou M, et al.. Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a systematic review and meta-analysis. BMC Gastroenterol. 2024, 24:58. 10.1186\/s12876-024-03134-w","journal-title":"BMC Gastroenterol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000000981","article-title":"Bevacizumab side effects and adverse clinical complications in colorectal cancer patients: review article","volume":"85","author":"Minhajat R","year":"2023","unstructured":"Minhajat R, Harjianti T, Islam IC, et al.. Bevacizumab side effects and adverse clinical complications in colorectal cancer patients: review article. Ann Med Surg (Lond). 2023, 85:3931-7. 10.1097\/MS9.0000000000000981","journal-title":"Ann Med Surg (Lond)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70341-9","article-title":"Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care","volume":"11","author":"Bose D","year":"2010","unstructured":"Bose D, Meric-Bernstam F, Hofstetter W, et al.. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol. 2010, 11:373-382. 10.1016\/S1470-2045(09)70341-9","journal-title":"Lancet Oncol"},{"key":"ref15","article-title":"Abdominal aneurysm rupture with aorto-caval fistula after bevacizumab therapy: a case report","volume":"3","author":"Capron T","year":"2018","unstructured":"Capron T, Beranger F, Goutorbe P, et al.. Abdominal aneurysm rupture with aorto-caval fistula after bevacizumab therapy: a case report. J Respir Med Lung Dis. 2018, 3:1031.","journal-title":"J Respir Med Lung Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1189910","article-title":"Aortic dissection induced by vascular endothelial growth factor inhibitors","volume":"14","author":"Dai S","year":"2023","unstructured":"Dai S, Zhong Y, Cui H, et al.. Aortic dissection induced by vascular endothelial growth factor inhibitors. Front Pharmacol. 2023, 14:1189910. 10.3389\/fphar.2023.1189910","journal-title":"Front Pharmacol"},{"key":"ref17","article-title":"Vascular endothelial growth factor\/vascular permeability factor (VEGF\/VPF) in normal and atherosclerotic human arteries","volume":"150","author":"Couffinhal T","year":"1997","unstructured":"Couffinhal T, Kearney M, Witzenbichler B, et al.. Vascular endothelial growth factor\/vascular permeability factor (VEGF\/VPF) in normal and atherosclerotic human arteries. Am J Pathol. 1997, 150:1673-85.","journal-title":"Am J Pathol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2017.08.012","article-title":"Bevacizumab-induced hypertension: Clinical presentation and molecular understanding","volume":"182","author":"Li M","year":"2018","unstructured":"Li M, Kroetz DL. Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther. 2018, 182:152-60. 10.1016\/j.pharmthera.2017.08.012","journal-title":"Pharmacol Ther"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-007-0664-8","article-title":"Clinical pharmacokinetics of bevacizumab in patients with solid tumors","volume":"62","author":"Lu JF","year":"2008","unstructured":"Lu JF, Bruno R, Eppler S, et al.. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol. 2008, 62:779-86. 10.1007\/s00280-007-0664-8","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12666","article-title":"Bevacizumab and wound-healing complications: a systematic review and meta-analysis of randomized controlled trials","volume":"7","author":"Zhang H","year":"2016","unstructured":"Zhang H, Huang Z, Zou X, Liu T. Bevacizumab and wound-healing complications: a systematic review and meta-analysis of randomized controlled trials. Oncotarget. 2016, 7:82473-81. 10.18632\/oncotarget.12666","journal-title":"Oncotarget"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/SAP.0b013e3181828141","article-title":"A review on bevacizumab and surgical wound healing: an important warning to all surgeons","volume":"62","author":"Gordon CR","year":"2009","unstructured":"Gordon CR, Rojavin Y, Patel M, et al.. A review on bevacizumab and surgical wound healing: an important warning to all surgeons. Ann Plast Surg. 2009, 62:707-9. 10.1097\/SAP.0b013e3181828141","journal-title":"Ann Plast Surg"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/367284-rupture-of-abdominal-aortic-aneurysm-after-bevacizumab-treatment-for-colorectal-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T13:56:47Z","timestamp":1752328607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/367284-rupture-of-abdominal-aortic-aneurysm-after-bevacizumab-treatment-for-colorectal-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,12]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.87776","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,12]]}}}